OUR BLOG
Latest Updates & News
At vero eos et accusamus iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos at dolores molestias excepturi sint occaecati cupiditate.
Qualitative study on COVID-19 avoidance behavior after lockdown
Abstract Background: This exploratory qualitative study involved semi-structured interviews with adults and caregivers...
P95 At Vaccine World Asia Congress
P95 successfully exhibited at the Vaccine World Asia Congress 2024, held on 6-7 November in Bangkok, Thailand. The...
P95 At World Vaccine Congress Europe 2024
This October, the P95 team attended and exhibited at Europe's largest vaccine event, the World Vaccine Congress Europe...
P95 Webinar Explores Insights to Conducting Clinical Trials in Africa
Join P95 for its webinar on Insights to conducting clinical trials in Africa, on 5 November.
Systematic Literature Review: Effect of pneumococcal conjugate vaccines on viral respiratory infections
In addition to preventing pneumococcal disease, emerging evidence indicates that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract infections (RTIs) by affecting pneumococcal-viral interactions.
P95 Acquires Assign DMB, Expanding Data Management and Biostatistics Services
P95, a leading global provider of epidemiology and clinical solutions with a specialty focus on vaccines and infectious diseases, is excited to announce the acquisition of Assign DMB.
P95 Transforming Exercise into Charitable Impact
At P95, we believe in the power of movement – not just as a means to personal health, but as a catalyst for global change. Our Strava group, an initiative that promotes health and fitness within the team, has successfully translated the time logged over the last year into substantial donations for three charities that make a real difference.
Laurence De Moerlooze Joins P95 as Chief Medical Officer
P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).
P95 Acquires 4Clinics to Expand Global CRO Services, Strengthen Position as Market Leader
P95 BV, is excited to announce the strategic acquisition of 4Clinics, a Contract Research Organization providing Data Management, Biostatistics, Scientific Writing, Regulatory Affairs and Clinical Operations services for clinical and epidemiological studies.
Celebrating P95’s Anniversary: From our Humble Beginnings to a Global Full-Service CRO
As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey!
P95 Expands its Global Presence with a New USA Office
P95 has opened its first office in the USA. Based in the Research Triangle Park in North Carolina, the largest research park in the USA, this expansion underlines P95s commitment to delivering high-quality research solutions to our clients and partners across the globe.
Symptomatic Respiratory Syncytial Virus Infection Incidence in Adults in Multiple Countries
Estimating respiratory syncytial virus (RSV) burden in adults is challenging because of non-specific symptoms, infrequent standard-of-care testing, resolution of viral shedding before seeking medical care, test positivity that varies by specimen site in the upper airway and lower diagnostic test sensitivity compared to children.
P95’s Journey From Epidemiology Consulting to Comprehensive CRO
In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).
Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.
Respiratory Syncytial Virus-Related Hospitalizations and Deaths Among Children and Adults in Spain
Respiratory syncytial virus (RSV) causes a substantial disease burden among infants. In older children and adults, incidence is underestimated due to nonspecific symptoms and limited standard-of-care testing. We aimed to estimate RSV-attributable hospitalizations and deaths in Spain during 2016-2019.
P95 welcomes John O’Brien as Chief Business Officer
We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.
COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases
id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in real-life in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals.
P95 Attends National Clinical Research Network Thailand 2023
P95 took center stage at a pivotal event in Thailand’s clinical research scene—the National Clinical Research Network (NCRN) Conference 2023.
Vaccination Programmes Book On Epidemiology, and Monitoring
Our P95 colleague Kaatje Bollaerts is excited to announce that the book ‘Vaccination Programmes | Epidemiology, Monitoring, Evaluation’ by Susan Hahné, Kaatje Bollaerts, and Paddy Farrington is now available to all to view and use online through a new open-access grant provided by CEPI.
OnQ joins the P95 family
P95 has signed an agreement to merge OnQ Research (“OnQ”) into P95. The transaction, furthers P95’s goal of becoming the leading global, vaccine-focused CRO. P95 now has unparalleled expertise conducting research in emerging geographies on the infectious diseases which could possibly drive a future pandemic.
P95 Attends Infectology Congress in Buenos Aires
Last week, P95 attended for the first time, the Congreso de Infectología 2023 organized by Asociación Panamericana de Infectología (API) and Sociedad Argentina de Infectología (SADI), which took place in Buenos Aires, Argentina.
This congress gathered renowned experts from the field of infectology, who shared lessons learnt and debated the most pressing and current topics on this topic.
More about the congress: https://www.congresosadi.com/